We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Gary Roubin MD, PhD

Gary S Roubin MD, PhD

Director and Physician-in-Chief, Cardiovascular Service Line, Continuum Cardiovascular Centers of New York (Beth Israel Medical Center, St. Luke’s and Roosevelt Hospital Centers), New York, New York

Dr. Gary Roubin is an internationally renowned interventional cardiologist recognized for his groundbreaking work in the development of the first FDA-approved coronary stent, as well as pioneering the techniques of carotid stenting and embolic protection devices. He is currently the Director and Physician in Chief of the Cardiovascular Service Line, Continuum Cardiovascular Centers of New York (Beth Israel Medical Center, St. Luke’s and Roosevelt Hospital Centers). He came to New York City in 1997 to begin a distinguished 15-year career at Lenox Hill Hospital, initially as Chief of Endovascular Services, and later in 2004, as the Chairman of the Department of Cardiovascular Medicine, the Director of the Cardiovascular Interventional Suites, and the President of the Medical Board. Dr. Roubin’s primary focus has been the full collaborative integration of interventional and clinical cardiologists, vascular surgeons, radiologists and other specialists to further innovation, research, excellence in patient care and active physician participation in operational efficiency and cardiovascular care delivery models.

Dr. Roubin came to Emory University in 1984 on a postdoctoral research grant from the National Heart Foundation of Australia to study under Andreas Gruentzig. In October of 1987, he placed the first coronary stent in a patient in the United States. Since then, his interests have included the development of device technology and innovative techniques for the treatment of coronary and peripheral atherosclerosis. He was Director of Research at the Andreas Gruentzig Cardiovascular Center of Emory University, and Professor of Medicine and Radiology at the University of Alabama at Birmingham before coming to New York in 1997. He was Co-Principal investigator in the NIH sponsored EAST study and was the lead U.S. Angioplasty operator in the NIH sponsored BARI trial, both comparing PCI and bypass surgery in patients with multivessel disease. He was the Co-Principal Investigator of the recently concluded NIH/CREST Study that has established the efficacy of carotid stenting for treatment of carotid artery stenosis. He is a Fellow of the American College of Cardiology, the Royal Australasian College of Physicians, the Council on Clinical Cardiology of the American Heart Association and numerous other professional societies. Dr. Roubin has published over 250 articles in peer review journals and and edited textbooks on interventional cardiovascular medicine. He lectures extensively and has received numerous awards for his notable contributions to cardiac and vascular care. His pioneering work has been seen live in teaching courses around the world for over 25 years.